The "Filgrastim Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com’s offering. Major players in the filgrastim biosimilars market are ...
The FINANCIAL — Sandoz, a Novartis company, announced on September 3 that Zarxio(TM) (filgrastim-sndz) is now available in the United States. Zarxio is the first biosimilar approved by the US Food and ...
Association of Community-Level Social Vulnerability With Clinical Trial Discussion and Participation Among Cancer Survivors This was an observational, noninferiority, cohort study of patients from ...
It’s been a decade since Sandoz Inc. launched Zarxio, referencing Amgen Inc.’s Neupogen (filgrastim), as the first biosimilar in the U.S. Zarxio was expected to be the beginning of a biosimilar boom ...
(Reuters) - U.S. regulators have accepted an application by Sandoz - the generics arm of Novartis - seeking approval for a copycat version of Amgen's drug Neupogen, or filgrastim, for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results